Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
12:13pm, Tuesday, 29'th Oct 2024
Novartis AG (NYSE:NVS ) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirs
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
11:25am, Tuesday, 29'th Oct 2024
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
Novartis CEO on the impact of the U.S. election for pharma
11:00am, Tuesday, 29'th Oct 2024
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Tuesday, 29'th Oct 2024
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compa
Novartis Posts Results Above Estimates, Raises Outlook
07:40am, Tuesday, 29'th Oct 2024
Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.
The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies
05:30am, Tuesday, 29'th Oct 2024
Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.
Novartis hikes FY forecast after Q3 profit beat
03:58am, Tuesday, 29'th Oct 2024
Novartis posts Q3 earnings with 10 per cent sales growth and 20 per cent core income growth. The drug maker has also hiked its FY guidance.
Novartis: we are exploring obesity drugs but other areas provide growth for years
03:42am, Tuesday, 29'th Oct 2024
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provi
Novartis lifts 2024 guidance for 3rd time on wider use of its drugs
02:10am, Tuesday, 29'th Oct 2024
Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (
This Biotech Stock Has Doubled Its Value Today—Here's Why
03:06pm, Monday, 28'th Oct 2024
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its tr
Buy 3 Stocks Likely to Gain on Potential Q3 Earnings Beat
03:01pm, Monday, 28'th Oct 2024
We have narrowed our search to three large-cap stocks set to report earnings results tomorrow. These are: NVS, RDDT, CHKP.
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
02:27pm, Monday, 28'th Oct 2024
Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial da
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
02:10pm, Monday, 28'th Oct 2024
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Novartis AG (NVS) Renal Portfolio Update Call Transcript
01:32pm, Monday, 28'th Oct 2024
Novartis AG (NYSE:NVS ) Renal Portfolio Update Conference Call October 28, 2024 8:00 AM ET Company Participants Sloan Simpson - Head, Investor Relations Shreeram Aradhye - President, Global Drug Devel
